Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
CORAL GABLES, Fla., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it has been named on the BioSpace 2025 Best Places to Work. Catalyst is among 50 U.S. operating employers on the Best Places to Work list. The recipients are recognized as the most sought-after in the industry by the life sciences community.
佛罗里达州科拉尔盖布尔斯，2024年11月13日（环球新闻）-- catalyst pharmaceuticals, Inc.（"Catalyst"或"公司"）（纳斯达克：CPRX），是一家商业阶段的生物制药公司，专注于许可、开发和商业化用于罕见和难以治疗疾病的创新药物，今天宣布已被列入BioSpace 2025最佳工作场所。Catalyst是美国最佳工作场所名单上的50家运营雇主之一。获得此荣誉的是生命科学社区中最受欢迎的行业/company。
"We are honored to be recognized by BioSpace as one of the Best Places to Work in 2025," said Richard J. Daly, President and Chief Executive Officer. "Our goal has always been to create an environment that fosters growth, development, and trust, while enabling our team members to fulfill their passion for improving patient care. This award celebrates the dedication of our incredible team, and their steadfast, patient-focused approach is making an important impact in addressing unmet needs of those living with rare diseases."
"我们很荣幸被BioSpace评选为2025年度最佳工作场所之一，"总裁兼首席执行官理查德·J·达利表示。"我们的目标始终是创造一个促进成长、发展和trust的环境，同时使我们的团队成员能够实现他们改善患者护理的热情。这项奖项庆祝我们这个incredible团队的奉献精神，他们坚持以患者为中心的方法在满足罕见疾病患者的未被满足需求上产生了重要影响。"
The BioSpace 2025 Best Places to Work list highlights a company's desirability in the recruitment marketplace, based on votes and ratings from thousands of members of the life sciences community. BioSpace evaluates each organization's merits with a focus on culture, career growth and development opportunities, leadership, and innovation. Nominations for Best Places to Work were opened in June 2024. Voting was conducted in August 2024. BioSpace reviewed the votes and rankings submitted by over 3,000 life sciences professionals. Respondents were asked to identify their top three most desirable biopharma companies, segmented by large (more than 1,000+ employees) and small (less than 1,000 employees) companies. Respondents were also asked to rate their top choice organization on attributes including compensation, innovation, career growth opportunities, leadership, culture, diversity, equity and inclusion, reputation, and flexibility and remote work.
BioSpace 2025最佳工作场所名单强调了一家公司在招聘市场上的吸引力，基于来自成千上万生命科学社区成员的投票和评分。BioSpace评估每个组织的优点，重点关注文化、职业成长和发展机会、领导力和创新。最佳工作场所的提名于2024年6月开放。投票于2024年8月进行。BioSpace审核了3000多名生命科学专业人士提交的投票和排名。受访者被要求识别他们心目中最理想的三家生物制药公司，分为大型（超过1000名员工）和小型（少于1000名员工）公司。受访者还被要求在属性上评估他们的首选组织，包括薪酬、创新、职业发展机会、领导力、文化、多样性、公平和包容、声誉以及灵活性和远程办公概念。
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst is headquartered in Coral Gables, FL., and was recognized on the Forbes 2024 list as one of America's most successful small-cap companies.
关于catalyst pharmaceuticals
catalyst pharmaceuticals, Inc. (纳斯达克：CPRX) 是一家专注于改善罕见疾病患者生活的生物制药公司。凭借将改变生活的治疗方案带入市场的成功记录，我们专注于持证入境、商业化和开发创新疗法。在对患者护理的深切承诺指导下，我们重视可及性，通过一套设计为提供无缝访问和持续援助的全面支持服务，确保患者获得所需护理。责任位于佛罗里达州科勒尔盖布尔斯，同时积极寻求通过战略合作伙伴关系扩大其全球商业版图。Catalyst 荣获福布斯2024年最成功的小市值公司之一的殊荣。
For more information, please visit Catalyst's website at .
更多信息, 请访问catalyst的网站 。
Forward-Looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2023 and its other filings with the U.S. Securities and Exchange Commission ("SEC"), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.
前瞻性声明
本新闻稿包含前瞻性声明，如1995年《私人证券诉讼改革法》的定义。前瞻性声明涉及已知和未知的风险和不确定性，可能导致催化剂未来期间的实际结果与预测结果有所不同。包括催化剂在2023财年年报10-K及其提交给美国证券交易委员会（“SEC”）的其他文件中描述的因素在内，可能会对催化剂产生不利影响。催化剂提交给SEC的文件可从SEC获取，在催化剂的网站上找到或在催化剂提出请求时获得。催化剂不承担更新此处所包含信息的任何义务，该信息仅在本日期前发表。
Source: Catalyst Pharmaceuticals, Inc.
来源：catalyst pharmaceuticals
Investor Contact
Mary Coleman, Catalyst Pharmaceuticals, Inc.
(305) 420-3200
mcoleman@catalystpharma.com
Media Contact
David Schull, Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
投资者联系人
Catalyst Pharmaceuticals，Inc.的Mary Coleman。
（305）420-3200
mcoleman@catalystpharma.com
媒体联系
David Schull，Russo Partners
(858) 717-2310
david.schull@russopartnersllc.com
Source: Catalyst Pharmaceuticals, Inc.
来源：catalyst pharmaceuticals
译文内容由第三方软件翻译。
